海外の治験の状況「%E8%84%B3%E5%8D%92%E4%B8%AD」での検索結果
334件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Authorised
- "Ensayo clínico multicéntrico, longitudinal, prospectivo, fase IV que compara dos técnicas de imagen (ImaTx y DXA) para evaluar el efecto anabólico de la PTH (1-84) en mujeres postmenopáusicas con osteoporosis primaria" "Multi-centre, longitudinal, prospective, phase IV clinical trial to compare two image technologies (ImaTx and DXA) assessing the anabolic effects of PTH (1-84) in postmenopausal women with primary osteoporosis" - STEP
- "Prymary postmenopausal osteoporosis" "Osteoporosis primaria postmenopáusica" MedDRA version: 9.1 Level: LLT Classification code 10031285 Term: Osteoporosis postmenopausal
- Spain
- 2007-07-24
Authorised
- Treatment of neuroendocrine tumours with genetically modified adenovirus
- Neuroendocrine tumors (NETs) are a heterogeneous group of neoplasms with varying symptoms, tumor biology and treatment response. NETs may occur in any organ, most commonly they are observed in the gastroenteropancreatic system and lungs. Most NET patients are diagnosed at advanced stage, 65% of them will die within 5 years. The only curative treatment is surgery with complete resection of the primary tumor. However, more than 50% of patients exhibit metastatic disease, where there is no cure. MedDRA version: 18.1 Level: PT Classification code 10071542 Term: Neuroendocrine carcinoma metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Sweden
- 2015-09-27
Authorised
- An open label, parallel group, multiple dose Phase III clinical study in patients with prostate cancer to investigate the clinical efficacy and safety of two new GnRH implants (AMW Goserelin 3.6 mg Implant and AMW Leuprorelin 3.6 mg Implant) applied every 28 days for 84 days - AMW/001/C
- prostate cancer
- Germany
- 2009-11-18
Authorised
- An open label, multiple dose Phase III clinical study in patients with prostate cancer to investigate the clinical efficacy and safety of a new GnRH implant (ACINO Goserelin 10.8 mg Implant) applied every 84 days for 168 days - C_30060_P3_03
- prostate cancer MedDRA version: 12.0 Level: LLT Classification code 10060862 Term: Prostate cancer
- Germany
- 2009-10-13
Authorised
- An open label, multiple dose Phase III clinical study in patients with prostate cancer to investigate the clinical efficacy and safety of a new GnRH implant (AMW Goserelin 10.8 mg Implant) applied every 84 days for 168 days - AMW/002/C
- prostate cancer
- Germany
- 2010-11-15
Authorised
- Adding the magnesium to normal anesthetic increases the effect of the same one?
- Hallux valgus correction MedDRA version: 16.1 Level: LLT Classification code 10011123 Term: Correction Hallux Valgus System Organ Class: 100000004865 ;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03]
- Italy
- 2013-12-16
Authorised
- OBE022 added-on to atosiban in threatened spontaneous preterm labour, Proof of Concept study
- oral treatment of threatened spontaneous preterm labour in weeks 24 to 34 of pregnancy MedDRA version: 20.1 Level: LLT Classification code 10075863 Term: Preterm labor System Organ Class: 100000004868 ;Therapeutic area: Body processes [G] - Reproductive physiologi cal processes [G08]
- Czech Republic, Finland, Israel, Poland, Russian Federation, Spain, Vietnam
- 2017-08-11
Authorised
- Influence du traitement par Pioglitazone sur l'Ostéoprotégérine dans le diabète de tye II - IPODia
- Diabète de type II MedDRA version: 9.1 Level: LLT Classification code 10045242 Term: Type II diabetes mellitus
- France
- 2007-04-23
Authorised
- Etude de l'effet de la pioglitazone dans l'ataxie de Friedreich : étude "preuve de concept" - ACTFRIE
- Ataxie de Friedreich MedDRA version: 8.1 Level: PT Classification code 10017374 Term: Friedreich's ataxia
- France
- 2008-08-21
Authorised
- Protective effect of gonadoliberin analogues on endocrine and reproduction ovarian function during antitumour treatment in young girls and women in fertile period: Project of pharmacological gonadal protection and protection of reproduction functions.
- The patient with diagnosis: Hodgkin disease and leukaemia. Patients starting at adolescence (B3 - B4 for breast development accordig Tanner criteria) till 34 years be included.
- Czech Republic
- 2008-03-04
